MedPath

A clinical trial to study the effects of two different protocols of cetrorelix injection timings in IUI cycles in infertile wome

Not Applicable
Completed
Conditions
Health Condition 1: null- Infertility
Registration Number
CTRI/2014/12/005289
Lead Sponsor
ot applicable
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
45
Inclusion Criteria

1)Unexplained infertility;

2)Mild male factor infertility;

3)Ovulation dysfunction infertility with previously failed induction with letrozole or clomiphene;

4)At least one patent fallopian tube;

5)BMI 18.5â??29.9 kg/m2

6)Euthyroid state

7)No associated medical problems like diabetes mellitus or Hypertension or Drug allergies.

Exclusion Criteria

1)Severe male factor infertility;

2)Stage III or IV endometriosis;

3)Tubal Factor Infertility;

4)baseline FSH >12 IU/L;

5)Less than four antral follicles per ovary

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Premature luteinization rate <br/ ><br>2.Ovulation ratesTimepoint: 1. If LH more than 10 mIU/ml and Progesterone more than 2ng/ml on day 10 and/or day 12 of menstrual cycle <br/ ><br>2. Documented by transvaginal ultrasound after 36 hours of ovulation trigger
Secondary Outcome Measures
NameTimeMethod
1.Pregnancy rate <br/ ><br>2.Endometrial thickness <br/ ><br>3.Adverse effects like ovarian hyperstimulation syndrome and multiple pregnancies <br/ ><br>4.Cycle cancellation rate <br/ ><br>Timepoint: 1.Positive urine pregnancy test after 15 days of IUI <br/ ><br>2.Thickness measurement on the day of dominant follicle (more than or equal to 18 mm size) <br/ ><br>3.Checked on the day of positive urine pregnancy test or in a symptomatic patient <br/ ><br>4.If no dominant follicle by day 18 of the cycle
© Copyright 2025. All Rights Reserved by MedPath